Capsulution NanoScience AG has commenced two feasibility studies in the area of pharmaceutical formulation (drug delivery) that have been commissioned by two renowned industrial clients.
Using the proprietary LBL-Technology, both studies aim at increasing the bioavailability of several new chemical entities (NCEs) in the human body.
Particularly the transport of water insoluble compounds like a wide range of drug candidates in the development pipelines of pharmaceutical companies will be optimized during the studies.
“We are receiving a great deal of interest from drug manufacturers in our patented technology,” said Maria González Ferreiro, Director Business Development of Capsulution NanoScience AG.
“Both studies are aimed at close adaptations of our patented LBL-Technology® to the requirements of the pharmaceutical industry.”